2 citations
,
December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.
December 2025 in “International Journal of Innovative Technologies in Social Science” This review suggests that while estrogen-targeted therapies may improve skin quality in postmenopausal women, systemic risks limit hormone replacement therapies, and more research is needed for localized treatments.
November 2022 in “Journal of the Endocrine Society” In this case study, a woman with high 25(OH)D levels and persistent symptoms showed decreased parathormone after transdermal estrogen therapy, highlighting the importance of assessing both parathormone and estrogen levels in similar patients.
October 2024 in “Journal of the Endocrine Society” In this retrospective chart review, researchers observed that estrogen monotherapy effectively suppressed testosterone levels below 50ng/dL in all transfeminine patients studied, particularly those using injectable formulations, though the small sample size and ongoing data collection limit these findings.
October 2024 in “Journal of the Endocrine Society” In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.